Synergistic neutralization of a chimetic SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins

AIDS Research and Human Retroviruses

Volumn 13, Issue 8, 1997, Pages 647-656

  Li, A N ^a,b   Baba, Timothy W ^a,b,c   Sodroski, Joseph ^a,b   Zolla Pazner, Susan ^d,e   Gorny, Miroslaw K ^e   Robinson, James ^f   Posner, Marshall R ^b,g   Katinger, Hermann ^h   Barbas III, Carlos F ⁱ   Burton, Dennis R ⁱ   Chou, Ting Chao ^j   Ruprecht, Ruth M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

ⁱ SCRIPPS RESEARCH INSTITUTE   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VPU PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CHIMERA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; ANIMAL; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MACACA; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, VIRAL; CELLS, CULTURED; CHIMERA; DRUG SYNERGISM; GENE PRODUCTS, VPU; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNOGLOBULINS; MACACA MULATTA; NEUTRALIZATION TESTS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 0030612105     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.647     Document Type: Article

References (40)

1. Mofenson LM, Wright PF, and Fast PE: Summary of the working group on perinatal intervention. AIDS Res Hum Retroviruses 1992; 8:1435-1438.
2. Baba TW, Sampson JE, Fratazzi C, Greene MF, and Ruprecht R: Maternal transmission of the human immunodeficiency virus: Can it be prevented? J Women's Health 1993;2:231-242.
3. Rusche JR, Javaherian K, McDanal C, Petro J, Lynn DL, Grimaila R, Langlois A, Gallo RC, Arthur LO, Fischinger PJ, Bolognesi DP, Putney SD, and Matthews TJ: Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino-acid sequence of the viral envelope gp120. Proc Natl Acad Sci USA 1988;85:3198-3202.
4. Matthews T, Langlois A, Robey W, Chang N, Gallo R, Fischinger R, and Bolognesi D: Restricted neutralization of divergent human T-lymphotropic virus type III isolated by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci USA 1986;83:9709-9713.
5. Nara PL, Robey WG, Pyle SW, Hatch WC, Dunlop NM, Kelliher JC, Arthur LO, and Fischinger PJ: Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J Virol 1988;62:2622-2628.
6. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, Koenig S, and Zolla-Pazner S: Neutralization of diverse HIV-1 variants by an anti-V3 human monoclonal antibody. J Virol 1992;66:7538-7542.
7. Jahaverian K, Langlois AJ, LaRosa FJ, Profy AT, Bolognesi DP, Herlihy WC, Putney SD, and Matthews TJ: Broadly neutralizing antibodies elicited by the hypervariable neutralizing determining of HIV-1. Science 1990;250:1590-1593.
8. Ohno T, Terada M, Yoneda Y, Shea KW, Chambers RF, Stroka DM, Nakamura M, and Kufe DW: A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120. Proc Natl Acad Sci USA 1991;88:10726-10729.
9. Skinner M, Langlois A, McDanal C, McDougal JS, Bolognesi D, and Matthews T: Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol 1988;62:4195-4200.
10. Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, Sun NC, and Robinson JE: Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 1991;65:489-493.
11. Karwowska S, Gorny MK, Buchbinder A, Gianakakos V, Williams C, Fuerst T, and Zolla-Pazner S: Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retroviruses 1992;8:1099-1106.
12. Posner MR, Cavacini LA, Emes CL, Power J, and Byrn R: Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr 1993; 6:7-14.
13. Tilley SA, Honnen WJ, Racho ME, Hilgartner M, and Pinter A: A human monoclonal antibody against the CD4 binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity. Res Virol 1991;142:247-259.
14. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, and Sodroski J: Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 1990;64:5701-5707.
15. McKeating JA, Cordell J, Dean CJ, and Balfe P: Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp120. Virology 1992;191:732-742.
16. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PWHI, Sawyer LSW, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, and Barbas CF III: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-1027.
17. Cavacini LA, Emes CL, Power J, Buchbinder A, Zolla-Pazner S, and Posner MR: Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J Acquir Immune Defic Syndr 1993;6:353-358.
18. Conley AJ, Kessler JA II, Boots LJ, Tung JS, Arnold BA, Keller PM, Shaw AR, and Emini EA: Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994;91:3348-3352.
19. Gorny MK, Xu JY, Karwowska S, Buchbinder A, and Zolla-Pazner S: Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993;150: 635-643.
20. Buchbinder A, Karwowska S, Gorny MK, Burda ST, and Zolla-Pazner S: Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retroviruses 1990;8:425-427.
21. Tilley SA, Honnen WJ, Racho ME, Chou TC, and Pinter A: Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res Hum Retroviruses 1992;8:461-467.
22. Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, and Zolla-Pazner S: Synergistic neutralization of human immunodeficiency virus type 1 by combination of human monoclonal antibodies. J Virol 1994;68:4001-4008.
23. Franchini G, Gurgo C, and Guo HG: Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency virus. Nature (London) 1987;328:539-543.
24. Letvin NL and King NW: Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Acquir Immune Defic Syndr 1990;3:1023-1040.
25. Li JT, Halloran M, Lord CI, Watson A, Ranchalis J, Fung M, Letvin NL, and Sodroski JG: Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol 1995;69:7061-7071.
26. Montefiori DC, Robinson WB Jr, and Schuffman SS: Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol 1988;26:231-235.
27. Goff S, Traktman P, and Baltimore D: Isolation and properties of Moloney murine leukemia virus: Use of a rapid assay for release of virion reverse transcriptase. J Virol 1981;38:239-248.
28. Chou T-C and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
29. Chou T-C: The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Synergism and Antagonism in Chemotherapy (Chou TC and Rideout DC, eds.). Academic Press, San Diego, California, 1991, pp. 61-102.
30. 50, synergism, antagonism, low-dose risk, receptor ligand binding and enzyme kinetics. Manual and software disk for IBM PC series. Biosoft, Cambridge, UK, 1989.
31. Reimann KA, Cate RL, Wu Y, Plamer L, Olson D, Waite BCD, Letvin NL, and Burkly LC: In vivo administration of CD4-specific monoclonal antibody: Effect on provirus load in rhesus monkeys chronically infected with the simian immunodeficiency virus of macaques. AIDS Res Hum Retroviruses 1995;11:517-524.
32. Putkonen P, Thorstensson R, Ghavamzadeh L, Albert J, Hild K, Biberfeld G, and Norrby E: Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature (London) 1991;352:436-438.
33. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, Eichberg JW, and Murthy KK: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (London) 1992;355:728-730.
34. Wyatt R, Thali M, Tilley S, Pinter A, Posner M, Ho D, Robinson J, and Sodroski J: Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region. J Virol 1992;66:6997-7004.
35. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, and Sodroski J: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993;67:3978-3988.
36. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, and Sodroski J: Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995;65:5723-5733.
37. Muster T, Steindl F, Purtscher M, Trkola A, Klims S, Himmler G, Rüker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-6647.
38. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF III, Burton DR, Ho DD, and Moore JP: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-6617.
39. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, and Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996;70:1100-1108.
40. Conley AJ, Gorny MK, Kessler JA II, Boots LJ, Ossorio-Castro M, Koenig S, Lineberger DW, Emini EA, Williams C, and Zolla-Pazner S: Neutralization of primary HIV-1 virus isolates by the broadly-reactive anti-V3 monoclonal antibody. J Virol 1994;68: 6994-7000.